Back to Search
Start Over
Adaptive radiotherapy in locally advanced esophageal cancer with atelectasis: a case report.
- Source :
-
BMC cancer [BMC Cancer] 2020 Jan 06; Vol. 20 (1), pp. 21. Date of Electronic Publication: 2020 Jan 06. - Publication Year :
- 2020
-
Abstract
- Background: To the best of our knowledge, no study has reported mediastinal shift accompanied with obstructive atelectasis due to bulky primary esophageal tumor components treated with adaptive radiotherapy and concurrent chemotherapy.<br />Case Presentation: Here we report the case of a 65-year-old male patient diagnosed with locally advanced thoracic esophageal squamous cell cancer, clinical T4bN1M0, stage IVA. Bronchoscopy and computed tomography (CT) revealed an almost complete obstruction of the lumen of the left bronchus due to compression by bulky primary esophageal tumor components. On admission, the patient presented with dyspnea and decreased arterial oxygen saturation. Chest radiography and CT on admission revealed mediastinal shift with left atelectasis, as opposed to findings from the chest radiography performed 26 days before admission. Because of the patient's overall good condition, we recommended definitive chemoradiotherapy instead of palliative bronchial stent placement. After obtaining the patient's consent, chemoradiotherapy was initiated on the following day and it comprised three-dimensional conformal radiotherapy with 60 Gy in 30 fractions with concurrent administration of cisplatin and 5-fluorouracil. During chemoradiotherapy, tumor location was monitored with cone-beam CT and chest radiography. Chemoradiotherapy on day 8 revealed no evidence of the mediastinal shift. CT simulation was reperformed to adjust the radiotherapy fields to account for geometrical changes induced by the absence of the mediastinal shift. Subsequently, the mediastinal shift and bronchial obstruction did not recur during the course of chemoradiotherapy. The patient completed the planned radiotherapy with concurrent and adjuvant chemotherapy, and no non-hematological grade ≥ 3 adverse events were observed. Complete response was confirmed 7 months after initiating chemoradiotherapy. Currently, no disease recurrence, dysphagia, or respiratory symptoms have been reported at 13 months after initiating chemoradiotherapy.<br />Conclusions: In this study, a bulky primary esophageal tumor caused mediastinal shift due to ipsilateral bronchial obstruction. The close follow-up for monitoring resolution of the mediastinal shift during the course of chemoradiotherapy enabled adequate dose delivery to targets, thus reflecting the geometrical changes induced by the absence of the mediastinal shift. Adaptive radiotherapy technique was crucial for favorable patient outcomes in this challenging clinical situation.
- Subjects :
- Aged
Antineoplastic Agents administration & dosage
Carcinoma, Squamous Cell diagnostic imaging
Carcinoma, Squamous Cell pathology
Carcinoma, Squamous Cell radiotherapy
Carcinoma, Squamous Cell therapy
Chemoradiotherapy adverse effects
Chemotherapy, Adjuvant adverse effects
Cisplatin administration & dosage
Deglutition Disorders etiology
Deglutition Disorders radiotherapy
Esophageal Neoplasms diagnostic imaging
Esophageal Neoplasms pathology
Esophageal Neoplasms radiotherapy
Fluorouracil administration & dosage
Humans
Male
Pulmonary Atelectasis diagnostic imaging
Pulmonary Atelectasis pathology
Pulmonary Atelectasis therapy
Remission Induction
Esophageal Neoplasms therapy
Mediastinum diagnostic imaging
Pulmonary Atelectasis etiology
Subjects
Details
- Language :
- English
- ISSN :
- 1471-2407
- Volume :
- 20
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- BMC cancer
- Publication Type :
- Academic Journal
- Accession number :
- 31906910
- Full Text :
- https://doi.org/10.1186/s12885-019-6505-4